At baseline, the levels of UBE2G2 and MAPKAP5 were elevated (4399.1 ± 152.8 vs 3525.3 ± 172.6 RFU of UBE2G2, T2D vs control, p < 0.01 and 705.1 ± 58.1 vs 561.6 ± 40.0, RFU of MAPKAP5, p < 0.05,) and the level of STUB1 was lower (519.02 ± 19.4 vs 671.4 ± 54.6 RFU of STUB1, T2D vs control, p < 0.05) in the T2D cohort (Fig. 2A–C). This evidence concerns the gene UBE2G2 and type 2 diabetes mellitus.